Antroquinonol - Golden Biotechnology Corporation

Drug Profile

Antroquinonol - Golden Biotechnology Corporation

Alternative Names: Hocena

Latest Information Update: 06 Dec 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Golden Biotechnology Corporation
  • Developer China Sky One Medical; Golden Biotechnology Corporation; Queensland University of Technology
  • Class Alkenes; Antidementias; Antineoplastics; Cyclohexenes; Ketones; Small molecules
  • Mechanism of Action Epidermal growth factor receptor modulators; Mitogen-activated protein kinase modulators; Proto oncogene protein c akt modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Hepatocellular carcinoma; Acute myeloid leukaemia; Pancreatic cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Colorectal cancer; Hyperlipidaemia; Non-small cell lung cancer; Pancreatic cancer
  • Preclinical Alzheimer's disease
  • No development reported Cancer

Most Recent Events

  • 01 Dec 2017 Golden Biotechnology receives patent for methods and compositions for treatment of Neurodegenerative disorders in USA
  • 01 Dec 2017 Phase-I/II clinical trials in Pancreatic cancer (First-line therapy, Late-stage disease, Metastatic disease, Combination therapy) in USA (PO) (NCT03310632)
  • 24 Oct 2017 Golden Biotechnology Corporation plans a phase I/II trial for Pancreatic Cancer (First-line therapy, Metastatic disease, Combination therapy), in November 2017 (NCT03310632)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top